BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

166.96

+8.81

(+5.57%)

At close: 04:00PM EDT

167.75

+0.79

(+0.47%)

After hours:

07:31PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Slow Stochastic

View all chart patterns

Performance Outlook

Previous Close	158.15
Open	159.88
Bid	165.00 x 1000
Ask	167.88 x 800
Day's Range	157.77 - 167.68
52 Week Range	121.32 - 464.00
Volume	1,069,952
Avg. Volume	1,549,190

Market Cap	40.574B
Beta (5Y Monthly)	-0.28
PE Ratio (TTM)	3.15
EPS (TTM)	53.01
Earnings Date	Aug 08, 2022
Forward Dividend & Yield	2.11 (1.26%)
Ex-Dividend Date	Jun 02, 2022
1y Target Est	263.78

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Undervalued

19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BNTX

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

BioNTech SE
Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
Rating
Fair Value
Economic Moat
19 days agoMorningstar

All

Zacks
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
- Here's Why Health Experts Aren't Worried About Monkeypox
  SheKnows
- COVID-19 in Oneida County: With cases falling, here's where vaccines, tests are available
  Utica Observer-Dispatch
Insider Monkey
Jim Cramer and Hedge Funds Agree on These 10 Stocks
In this article, we discuss the 10 stocks that Jim Cramer and hedge funds agree on. If you want to read about some more stocks that Jim Cramer and hedge funds agree on, go directly to Jim Cramer and Hedge Funds Agree on These 5 Stocks. In the past few weeks, Jim Cramer, the journalist […]
InvestorPlace
7 of the Best Cheap Stocks to Buy for the Second Half of 2022
Steep market corrections offer opportune entry points for investors searching some of the best cheap stocks. Alpha and Omega Semiconductor (AOSL): The chipmaker saw 28% annual revenue growth in the computer segment. Bark (BARK): Its Barkbox service continues to add subscribers and generate reliable recurring revenue. BioNTech (BNTX): Anticipates generating significant Covid-19 vaccine-related revenue for fiscal 2022. Daqo New Energy (DQ): Grew top line by 400% year-over-year thanks to a booming